Meisler M H, Kearney J, Ottman R, Escayg A
Department of Human Genetics, School of Medicine, University of Michigan, Ann Arbor, Michigan 48109-0618, USA.
Annu Rev Genet. 2001;35:567-88. doi: 10.1146/annurev.genet.35.102401.091142.
The development of molecular markers and genomic resources has facilitated the isolation of genes responsible for rare monogenic epilepsies in human and mouse. Many of the identified genes encode ion channels or other components of neuronal signaling. The electrophysiological properties of mutant alleles indicate that neuronal hyperexcitability is one cellular mechanism underlying seizures. Genetic heterogeneity and allelic variability are hallmarks of human epilepsy. For example, mutations in three different sodium channel genes can produce the same syndrome, GEFS+, while individuals with the same allele can experience different types of seizures. Haploinsufficiency for the sodium channel SCN1A has been demonstrated by the severe infantile epilepsy and cognitive deficits in heterozygotes for de novo null mutations. Large-scale patient screening is in progress to determine whether less severe alleles of the genes responsible for monogenic epilepsy may contribute to the common types of epilepsy in the human population. The development of pharmaceuticals directed towards specific epilepsy genotypes can be anticipated, and the introduction of patient mutations into the mouse genome will provide models for testing these targeted therapies.
分子标记和基因组资源的发展促进了人类和小鼠中导致罕见单基因癫痫的基因的分离。许多已鉴定的基因编码离子通道或神经元信号传导的其他成分。突变等位基因的电生理特性表明神经元兴奋性过高是癫痫发作的一种细胞机制。遗传异质性和等位基因变异性是人类癫痫的特征。例如,三种不同的钠通道基因突变可产生相同的综合征,即GEFS+,而具有相同等位基因的个体可能经历不同类型的癫痫发作。从头发生无效突变的杂合子中严重的婴儿癫痫和认知缺陷已证明钠通道SCN1A的单倍剂量不足。正在进行大规模患者筛查,以确定导致单基因癫痫的基因的不那么严重的等位基因是否可能导致人群中常见类型的癫痫。可以预期针对特定癫痫基因型的药物的开发,并且将患者突变引入小鼠基因组将为测试这些靶向疗法提供模型。